BioWorld MedTech

Aug. 26, 2010

Canaccord analyst sees robust M&A trends in cardio

The cardiovascular device sector should expect to see M&A activity to be more robust in the next couple of years than it has been in the last 20 to 30 years, according to one analyst who covers this space. (Medical Device Daily) Read More

F&S analyst: Device misuse key in causing medical errors

International report: Elekta's Gamma Knife used for the first time in Australia

Washington roundup: FDA seeks input on four pre-amendments devices

Financings roundup: Healthsense closes growth capital funding round

Deals roundup: Stryker in move to acquire Gaymar for nearly $150M

People in the News

Agreements/contracts: Cerus acquires rights to BioOne's Intercept

Grants roundup: Dynasil company wins $6.2M in DoE grants

Product Briefs

Patent watch: Celera gets gene-detecting patent for heart attack risk

MDD's Ortho Extra

MDD's food for med-tech thought

Today's news in brief

BioWorld

BioWorld briefs for Nov. 25, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 25, 2024.

J&J’s Ottava robotic system approved for US pivotal trial

BioWorld MedTech

Johnson & Johnson received U.S. FDA investigational device exemption to begin the pivotal clinical trial for the Ottava robotic surgical system. If the trial goes...

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...